In Italy, Cardioaspirin is produced without plastic.

In Italy the cardioaspirin It is actually one of the best-selling drugs: with approximately 36 million packs it is second only to tachypirin. For this reason, the innovation introduced at the Bayer plant in Garbagnate Milanese, in the province of Milan, is very important from a sustainability perspective. This is where the medicine is produced. without plastic: the news does not concern the blister pack of the tablets, but the external plastic film which wrapped the cartons containing the packages of cardioaspirin During packaging and logistics. The plant team redesigned the process so that the packages are inserted directly into the packaging boxes, completely eliminating this plastic film.

The benefits in terms of cost savings and waste reduction, especially plastic, are enormous. Every year, this eliminates 25 tons of polypropylene film, 5 million meters of plastic, 3.750 reels, and 70 tons of CO2. Furthermore, the production process also benefits in terms of lower costs, as it eliminates a step.

Bayer's Italian plant also produces the cardioaspirin Destined for both the European and, to a large extent, the Chinese markets, the plant is considered one of the group's most advanced worldwide. And the transformation that began here could soon spread to other Bayer plants, as well as other large pharmaceutical companies.

The elimination of the external plastic film introduced in the Garbagnate Milanese plant does not modify the medicine or its primary packaging (for example the blister containing the tablets). This is an innovation of process and secondary packaging, so it is potentially transferable to other products that use similar logistics.

It can be applied especially to: